<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393519</url>
  </required_header>
  <id_info>
    <org_study_id>NEPTUN2</org_study_id>
    <nct_id>NCT04393519</nct_id>
  </id_info>
  <brief_title>Non-invasive Evaluation Program for TIPS and Follow Up Network 2 (NEPTUN2)</brief_title>
  <acronym>NEPTUN2</acronym>
  <official_title>Non-invasive Evaluation of Prognostic Parameters for Patients With Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using a Structured Follow up Protocol 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of non-invasive prognostic parameters in patients receiving transjugular
      intrahepatic portosystemic shunt (TIPS) for complications of portal hypertension. Patients
      are cared according to the local standardized follow up program. Clinical and laboratory data
      from standard patient care are evaluated for potential prognostic value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NEPTUN consists of liver cirrhosis receiving transjugular intrahepatic portosystemic shunt
      (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a
      structured routine evaluation and follow up program. The diagnosis of cirrhosis was based on
      clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>death, liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascites</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of amount of ascites according to the Child-Score (0=none;1=moderate/treatable; 2=severe/refractory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Encephalopathy (HE)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of the grade according to the West Haven Criteria (Grade 0 (no HE) - Grade 4 (hepatic coma))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal Bleeding</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of presence of variceal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>defined as Bilirubin level â‰¥ 12mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute-on-Chronic Liver Failure (ACLF)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Presence of ACLF according to the EASL-Chronic liver Failure Consortium (CLIF)-criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failures</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of Organ failures according to CLIF-Sequential Organ Failure Assessment (SOFA) Score (Score 6 (best) to 18 (worst))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of AKI according to KDIGO definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sarcopenia</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of sarcopenia according to EASL-guideline definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-surgical survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of post-surgical survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <description>Prospective cohort that received TIPS from 05/12/2020 onwards</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS procedure</intervention_name>
    <description>Implantation of TIPS for portal hypertension</description>
    <arm_group_label>Prospective</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, stool, ascites, DNA, PBMC, Buffi coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving TIPS according to guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insertion of TIPS according to guidelines

        Exclusion Criteria:

          -  Contraindication for TIPS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Praktiknjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Praktiknjo, MD</last_name>
    <phone>+49(0)228-287 15770</phone>
    <email>michael.praktiknjo@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Chang, MD</last_name>
    <phone>+49(0)228-287 15770</phone>
    <email>johannes.chang@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Praktiknjo, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>michael.praktiknjo@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Chang, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>johannes.chang@ukbonn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Praktiknjo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>transjugular intrahepatic portosystemic shunt (TIPS)</keyword>
  <keyword>non-invasive assessments</keyword>
  <keyword>Transthoracic echocardiography (TTE) with Speckle-tracking</keyword>
  <keyword>Computer tomography scan (CT-scan)</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>Circulating biomarkers</keyword>
  <keyword>Electroencephalography (EEG)</keyword>
  <keyword>Elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

